سعر انجيكيناز 250000 وحدة دولية فيال 250 000 وحدة دولية 2022

Urokinase 250 000 IU powder vial for intravenous infusion, a thrombolytic (plasminogen activator) (Angikinase, Sedico, Egypt); 1 vial.

• Lysis of acute massive pulmonary embolism (obstruction or significant filling defects of two or more lobar arteries) or pulmonary embolism accompanied by unstable haemodynamicsPopulation: AdultsDailyMed (U.S. National Library of Medicine)

• Bleeding is the most frequent adverse reaction (from superficial sites to fatal internal haemorrhage).International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Allergic-type reactions and infusion reactions (fever, chills, rigors, nausea, vomiting, hypotension, hypoxia).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Active internal bleeding; recent (within 2 months) cerebrovascular accident, intracranial or intraspinal surgery; recent trauma including cardiopulmonary resuscitation.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Intracranial neoplasm, arteriovenous malformation or aneurysm; known bleeding diathesis; severe uncontrolled arterial hypertension.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Known hypersensitivity to urokinase or any component.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Bleeding, including fatal haemorrhage: avoid intramuscular injections and non-essential handling; perform arterial punctures at compressible sites; stop the infusion if serious bleeding occurs.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Anaphylaxis, allergic and infusion reactions (fever, chills, rigors, hypoxia, hypotension) have been reported.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Cholesterol embolisation has been reported rarely with thrombolytics.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Anticoagulants, antiplatelet agents and other thrombolytics (heparin, warfarin, aspirin, dipyridamole, GP IIb/IIIa inhibitors)Increased risk of serious bleeding.DailyMed (U.S. National Library of Medicine)

• Animal studies at high doses showed no fetal harm, but there are no adequate studies in pregnant women; use in pregnancy only if clearly needed.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Excretion in human milk is unknown; use with caution in nursing women.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Urokinase: Enzyme that converts plasminogen to the enzyme plasmin, which degrades fibrin clots as well as fibrinogen and other plasma proteins; plasma half-life about 12.6 minutes.